Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cutia Therapeutics ( (HK:2487) ) has provided an update.
Cutia Therapeutics has announced the latest composition of its board of directors, comprising executive directors Zhang Lele and Huang Yuqing, several non-executive directors, and three independent non-executive directors. The company has also detailed the membership and chairmanship of its three key board committees—Audit, Remuneration and Nomination—indicating which directors serve as members and which act as chairpersons, underscoring its emphasis on formalized governance and oversight structures as it continues to operate as a listed entity in Hong Kong.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics, incorporated in the Cayman Islands and listed in Hong Kong (stock code 2487), operates in the pharmaceutical and biotechnology sector, focusing on therapeutics development. The company is governed by a board structure that includes executive, non-executive and independent non-executive directors, reflecting the corporate governance standards expected of a listed healthcare group.
Average Trading Volume: 377,828
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.9B
For detailed information about 2487 stock, go to TipRanks’ Stock Analysis page.